IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.466
EU - Europa 4.204
AS - Asia 3.256
SA - Sud America 836
AF - Africa 95
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 13.887
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.333
SG - Singapore 1.321
DE - Germania 1.175
CN - Cina 1.099
SE - Svezia 740
BR - Brasile 685
UA - Ucraina 429
IT - Italia 424
FR - Francia 285
IE - Irlanda 227
GB - Regno Unito 220
PL - Polonia 202
IN - India 158
FI - Finlandia 146
ID - Indonesia 140
VN - Vietnam 130
RU - Federazione Russa 115
TR - Turchia 75
CA - Canada 66
HK - Hong Kong 66
JP - Giappone 56
BD - Bangladesh 46
BE - Belgio 46
MX - Messico 40
EC - Ecuador 39
ES - Italia 38
AR - Argentina 36
CI - Costa d'Avorio 32
NL - Olanda 32
IQ - Iraq 25
CL - Cile 24
AT - Austria 23
RO - Romania 22
AU - Australia 18
IL - Israele 18
PK - Pakistan 18
CO - Colombia 15
ZA - Sudafrica 15
UZ - Uzbekistan 14
KR - Corea 13
PE - Perù 13
CH - Svizzera 11
KE - Kenya 11
LT - Lituania 11
VE - Venezuela 11
SA - Arabia Saudita 10
AE - Emirati Arabi Uniti 9
PY - Paraguay 9
BG - Bulgaria 8
MA - Marocco 8
AZ - Azerbaigian 7
CZ - Repubblica Ceca 7
EG - Egitto 7
IR - Iran 7
TN - Tunisia 7
BZ - Belize 6
GR - Grecia 6
JO - Giordania 6
PT - Portogallo 6
A2 - ???statistics.table.value.countryCode.A2??? 5
OM - Oman 5
PR - Porto Rico 5
DK - Danimarca 4
DZ - Algeria 4
EU - Europa 4
LK - Sri Lanka 4
LU - Lussemburgo 4
NO - Norvegia 4
TH - Thailandia 4
AL - Albania 3
BY - Bielorussia 3
GA - Gabon 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LV - Lettonia 3
NI - Nicaragua 3
PA - Panama 3
PH - Filippine 3
UY - Uruguay 3
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
HN - Honduras 2
JM - Giamaica 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
A1 - Anonimo 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
Totale 13.875
Salva come PNG Salva come JPEG
Città #
Chandler 891
Singapore 614
Ashburn 523
Jacksonville 285
Beijing 232
San Mateo 230
Dublin 217
Warsaw 166
New York 161
Wilmington 155
Ann Arbor 154
Nanjing 141
Jakarta 133
Houston 128
Dearborn 116
Woodbridge 114
Boston 104
Cattolica 96
Los Angeles 94
Chicago 81
Hefei 79
Dallas 73
Princeton 71
Milan 69
Redwood City 69
Moscow 64
Hong Kong 63
Lawrence 61
São Paulo 60
Frankfurt am Main 55
North Bergen 55
Nürnberg 53
Seattle 51
Fairfield 49
Marseille 49
Munich 49
Bremen 46
Izmir 45
Nanchang 45
Fuzhou 42
Rome 41
Hangzhou 39
London 39
Brussels 38
Ho Chi Minh City 38
Redmond 37
Nuremberg 33
Abidjan 32
Hanoi 32
Shanghai 31
Mountain View 30
Tokyo 30
Santa Clara 27
Shenyang 27
Tianjin 27
Norwalk 25
Boardman 24
Hebei 24
Zhengzhou 24
Changsha 23
Düsseldorf 23
Helsinki 23
Turku 23
Brooklyn 21
Porto Alegre 19
Kunming 18
Rio de Janeiro 18
Belo Horizonte 17
Chennai 17
Kent 17
Leawood 16
Montreal 16
Orem 16
San Francisco 16
Buffalo 15
Des Moines 15
Fortaleza 15
Jiaxing 15
Millbury 15
Pune 15
Cambridge 14
San Jose 14
Tashkent 14
University Park 14
Washington 14
Guayaquil 13
New Delhi 13
Poplar 13
Stockholm 13
Wroclaw 13
Brasília 12
Campinas 12
Denver 12
Mexico City 12
Philadelphia 12
Dhaka 11
Falls Church 11
Guangzhou 11
Istanbul 11
Seoul 11
Totale 7.004
Salva come PNG Salva come JPEG
Nome #
International consensus guidance for management of myasthenia gravis: Executive summary 224
Myasthenia gravis 220
Single-centre 40-year results of redo operation for recurrent thymomas. 219
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 192
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 176
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 175
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 175
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 172
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 168
When myasthenia gravis is not all. 164
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 164
Thymoma in patients with MG: characteristics and long-term outcome 163
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 159
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 156
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 153
SFEMG: A piece in the diagnostic puzzle of myasthenia 152
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 152
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 150
A Genome-wide Association Study of Myasthenia Gravis 150
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 147
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 147
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 142
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 140
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 140
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 139
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 137
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 135
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 134
Anti-AChR-negative myasthenia gravis: clinical and immunological features 128
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 125
Response to therapy in myasthenia gravis with anti-MuSK antibody 125
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 125
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 122
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 121
Myasthenia gravis with antibodies to MuSK: an update 120
Multiple paraneoplastic diseases associated with thymoma. 119
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 119
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 119
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 119
BAFF serum levels in myasthenia gravis: effects of therapy 118
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 117
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 114
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 112
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 112
Determinants of cognitive impairment in elderly myasthenia gravis patients 111
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 111
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 108
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 108
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 107
Prognostic grading after complete resection for thymic malignancies 107
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 107
Diagnostic features and subtyping of thymoma lymph node metastases 106
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 105
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 104
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 104
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 104
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 104
Clinical heterogeneity of seronegative myasthenia gravis 103
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 102
Immunosuppressive therapies in myasthenia gravis 99
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 99
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 98
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 97
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 97
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 96
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 95
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 94
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 94
Spontaneous recovery from anti-NMDAR encephalitis 92
In sickness and in health: when myasthenia gravis is a conjugal matter 89
Acquired myasthenia gravis in childhood. 88
Thymoma recurrences in myasthenia gravis patients 88
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 87
Course and treatment of myasthenia gravis during pregnancy 86
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 86
Thymectomy in the treatment of myasthenia gravis: report of 247 patients 85
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 84
Risk of cancer in patients with myasthenia gravis 83
Antibody-phenotype correlation in stiff-person syndrome 83
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 83
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 83
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 83
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 83
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 82
Imatinib mesylate in thymic epithelial malignancies. 81
A practical guide to the recognition and management of myasthenia gravis 81
Early-onset myasthenia gravis: clinical characteristics and response to therapy 81
Myasthenia gravis during interferon alfa therapy 80
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 80
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 80
Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report 80
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 79
Myasthenia gravis and associated autoimmune diseases 78
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 78
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension 77
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 77
Myasthenia gravis: New developments in research and treatment 77
Anti-MuSK antibodies: Correlation with myasthenia gravis severity 77
Benefit and danger from immunotherapy in myasthenia gravis 77
Minimal manifestation status and prednisone withdrawal in the MGTX trial 76
Totale 11.544
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021698 0 0 0 0 135 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20252.252 54 90 181 60 171 66 72 119 376 172 455 436
2025/20262.587 954 176 358 805 294 0 0 0 0 0 0 0
Totale 14.064